Loading data for DXCM — first visit, this takes a few seconds.

DexCom, Inc. (DXCM)

NasdaqGS: DXCM · 即時價格 · USD

84.51

+0.63 (0.75%)

收盤價： Sep 10, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	84.49
市值	31.9B
營收 (ttm)	4.97B
淨利（ttm）	1000M
	1.42
	2.55
	33.14
	27.05
P/B (ttm)	12.17
P/S (ttm)	6.42
財報日期	Oct 29, 2026

賣價	91.13
成交量	3,488,741
20 日平均成交量	4,757,711
開盤價	83.27
前收盤價	83.88
當日區間	82.29 - 84.81
52 週範圍	54.11 - 92.59
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions;...

[閱讀更多]

產業 Medical Devices

類股 Healthcare

IPO 日期 Apr 14, 2005

員工 11,000

證券交易所 NasdaqGS

股票代號 DXCM

網站 https://www.dexcom.com

完整的公司簡介

財務表現

DexCom 在 2025 年的營收為 4.66B，較前一年的 4.03B 增加 15.6%。淨利為 836.3M，較前期增加 45.14%。

財務報表

財報驚奇

DexCom 已於 Jul 30, 2026 公布季度財報：

營收為 $1.31B 低於預期 $0, 年增 13.08% 成長.
每股盈餘為 0.7 超出預期 0.09, 年增 45.83% 成長.

下次財報發布

DexCom, Inc. 的下次財報預計於 Oct 29, 2026, 收盤後。
分析師預估營收 ... 升級

價格為何變動

新聞動態

18 小時前 · StockStory

3 Quality Compounders with Impressive Fundamentals

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

2 天前 · Barchart

DexCom Stock: Is DXCM Underperforming the Healthcare Sector?

DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.

1 週前 · Simply Wall St.

DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair

DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sit...

1 週前 · StockStory

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.

1 週前 · Barrons.com

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input...

第 1 頁，共 2 頁